Patents Assigned to TOKYO UNIVERSITY OF PHARMACY & LIFE SCIENCES
-
Publication number: 20240034787Abstract: The present invention relates to an optic nerve protecting agent containing an anti-low density lipoprotein receptor-related protein 1 (LRP1) antibody or an anti-LRP1 antibody fragment.Type: ApplicationFiled: November 26, 2021Publication date: February 1, 2024Applicants: TOKYO UNIVERSITY OF PHARMACY & LIFE SCIENCES, NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITIONInventors: Hideki Hayashi, Norio Takagi, Yamato Kikkawa, Haruhiko Kamada, Satoshi Nagata
-
Publication number: 20240024266Abstract: [Problem] To develop novel therapeutic agents for viral diseases such as coronavirus infections. [Solution] The present invention provides a therapeutic or prophylactic agent for viral diseases containing a compound with inhibitory activity against the function of Pin1 or a pharmaceutically acceptable salt thereof as an active ingredient.Type: ApplicationFiled: November 16, 2021Publication date: January 25, 2024Applicants: Hiroshima University, Tokyo University of Pharmacy & Life Sciences, The University of TokyoInventors: Tomoichiro Asano, Takemasa Sakaguchi, Takeshi Yamamotoya, Yusuke Nakatsu, Hisanaka Ito, Takayoshi Okabe, Jeffrey Encinas
-
Patent number: 11807612Abstract: The aim is to provide a novel compound that can luminesce with high brightness and be used as a luminescent substrate in a firefly bioluminescence system. Provided is a heterocyclic compound, or salt thereof, represented by the following general formula (1): [R1, R2, and R3 are independently hydrogen or an alkyl group having a carbon number of 1-4, with provisos that R1 and R2 are optionally bonded to form a ring and that one of R1 and R2 is optionally bonded to Y1 to form a ring; X is S, O, NR4, or CH2, and Y1 and Y2 are independently N or CR4, where each R4 is independently hydrogen, an alkyl group having a carbon number of 1-4, an alkenyl group having a carbon number of 2-4, or an acyl group having a carbon number of 2-4; n is an integer of 0-4].Type: GrantFiled: June 29, 2021Date of Patent: November 7, 2023Assignees: The University of Electro-Communications, TOKYO UNIVERSITY OF PHARMACY & LIFE SCIENCESInventors: Shojiro Maki, Nobuo Kitada, Ryohei Moriya, Hiroshi Aoyama, Ryosuke Ijuin
-
Publication number: 20230192635Abstract: The aim is to provide a novel compound that can luminesce with high brightness and be used as a luminescent substrate in a firefly bioluminescence system. Provided is a heterocyclic compound, or salt thereof, represented by the following general formula (1): [R1, R2, and R3 are independently hydrogen or an alkyl group having a carbon number of 1-4, with provisos that R1 and R2 are optionally bonded to form a ring and that one of R1 and R2 is optionally bonded to Y1 to form a ring; X is S, O, NR4, or CH2, and Y1 and Y2 are independently N or CR4, where each R4 is independently hydrogen, an alkyl group having a carbon number of 1-4, an alkenyl group having a carbon number of 2-4, or an acyl group having a carbon number of 2-4; n is an integer of 0-4].Type: ApplicationFiled: June 29, 2021Publication date: June 22, 2023Applicants: The University of Electro-Communications, TOKYO UNIVERSITY OF PHARMACY & LIFE SCIENCESInventors: Shojiro MAKI, Nobuo KITADA, Ryohei MORIYA, Hiroshi AOYAMA, Ryosuke IJUIN
-
Publication number: 20230133581Abstract: [Problem] To develop a group of novel compounds with an inhibitory activity against the function of Pin1 so as to use them as candidate compounds for medicaments.Type: ApplicationFiled: March 9, 2021Publication date: May 4, 2023Applicants: Hiroshima University, Tokyo University of Pharmacy & Life Sciences, The University of TokyoInventors: Tomoichiro Asano, Yusuke Nakatsu, Hisanaka Ito, Takayoshi Okabe
-
Publication number: 20230127046Abstract: A compound represented by the general formula (I) given below or a pharmacologically acceptable salt thereof has been found to have a strong G9a inhibitory effect. The compound (I) or the pharmacologically acceptable salt thereof inhibits G9a and thereby has high usefulness for the treatment, prevention or suppression of various pathological conditions (proliferative disease such as cancer, ?-globin abnormality, fibrosis, pain, neurodegenerative disease, Prader-Willi syndrome, malaria, viral infection, myopathy, autism, etc.).Type: ApplicationFiled: November 26, 2020Publication date: April 27, 2023Applicants: RIKEN, TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES, MICROBIAL CHEMISTRY RESEARCH FOUNDATIONInventors: Tatsunobu SUMIYA, Yosuke NISHIGAYA, Ryosuke NAMIE, Noriaki HASHIMOTO, Akihiro ITO, Fumiyuki SHIRAI, Ko KIKUZATO, Minoru YOSHIDA
-
Patent number: 11566047Abstract: Provided is a peptide having a short chain length, for example, having the number of amino acid residues of 20 or less and having a high myostatin inhibitory activity. The present invention is a peptide comprising an amino acid sequence represented by Formula (1) in the specification and having the number of amino acid residues of 20 or less.Type: GrantFiled: August 8, 2017Date of Patent: January 31, 2023Assignee: TOKYO UNIVERSITY OF PHARMACY & LIFE SCIENCESInventors: Yoshio Hayashi, Kentaro Takayama, Yoichi Negishi
-
Patent number: 11504379Abstract: The purpose of the invention is to develop, as drug-candidate compounds, a group of novel compounds having the activity of inhibiting functions of Pin1. The invention provides: a compound represented by formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic or prophylactic agent for inflammatory diseases, a therapeutic or prophylactic agent for cancer, and a therapeutic or prophylactic agent for adiposity that use said compound/salt.Type: GrantFiled: August 6, 2018Date of Patent: November 22, 2022Assignees: Hiroshima University, Tokyo University of Pharmacy & Life Sciences, The University of TokyoInventors: Tomoichiro Asano, Yusuke Nakatsu, Hisanaka Ito, Takayoshi Okabe
-
Publication number: 20220276231Abstract: The present invention provides a method for quantitatively detecting ?-1,3-1,6-glucan separately from ?-1,3-glucan and ?-1,3-1,4-glucan. The present invention is a method for measuring ?-1,3-1,6-glucan, the method including: a step for mixing ?-glucan in a test sample, a molecule that specifically binds to a ?-(1?3) bond, and a molecule that specifically binds to a ?-(1?6) bond to form a complex containing the molecule that specifically binds to a ?-(1?3) bond and the molecule that specifically binds to a ?-(1?6) bond; a step for detecting the complex; and a step for measuring the amount of ?-1,3-1,6-glucan in the test sample, on the basis of the results of the detection.Type: ApplicationFiled: May 18, 2022Publication date: September 1, 2022Applicants: OLYMPUS CORPORATION, Tokyo University of Pharmacy & Life SciencesInventors: Hidetaka NAKATA, Yoshiyuki ADACHI, Kenichi ISHIBASHI, Daisuke YAMANAKA, Naohito OHNO
-
Publication number: 20220226479Abstract: There is provided technology for promoting permeation of a substance into a cell layer. Provided is a cell layer permeation promoter comprising a compound represented by general formula (1). Also provided is a composition for facilitating drug absorption that contains the cell layer permeation promoter, said composition being for facilitating absorption of a drug into a living body. Also provided is a pharmaceutical composition that contains the cell layer permeation promoter and furthermore contains a drug to be absorbed into a living body.Type: ApplicationFiled: March 19, 2020Publication date: July 21, 2022Applicants: University of Tsukuba, Tokyo University of Pharmacy and Life SciencesInventors: Takeo USUI, Yoko NAGUMO, Minagi MUKAIYAMA, Yoshio HAYASHI, Atsuhiko TANIGUCHI, Chihiro UCHIYAMA
-
Patent number: 11345914Abstract: This is to provide a composition for delivering a nucleic acid and a nucleic acid-containing composition which ensure stability of a nucleic acid drug, have a high intracellular introduction rate, can efficiently express the function of a nucleic acid drug, and have low cytotoxicity. Disclosed is a composition for delivering a nucleic acid and a nucleic acid-containing composition each comprises a block copolymer in which a polyethylene glycol segment and a hydrophobic polyester segment are linked, and a peptide having 4 to 30 residues containing at least one selected from the group consisting of arginine and lysine.Type: GrantFiled: July 11, 2018Date of Patent: May 31, 2022Assignee: TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCESInventors: Takanori Kanazawa, Yuuki Takashima, Hisako Ibaraki, Shunsuke Shiraishi, Ei Nakata, Yusuke Iriyama, Keiichiro Otsuka
-
Patent number: 11203565Abstract: An object of the present invention is to develop a therapeutic agent for an inflammatory disease such as an inflammatory bowel disease or NASH, which therapeutic agent shows less side effects and high effectiveness. The present invention provides a compound represented by Formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic agent or a prophylactic agent for an inflammatory disease, and a therapeutic agent or a prophylactic agent for colon cancer, containing the compound.Type: GrantFiled: November 29, 2017Date of Patent: December 21, 2021Assignees: Hiroshima University, Tokyo University of Pharmacy & Life Sciences, The University of TokyoInventors: Tomoichiro Asano, Yusuke Nakatsu, Hisanaka Ito, Takayoshi Okabe
-
Patent number: 11071738Abstract: The purpose of the invention is to develop a novel therapeutic agent for fatty liver diseases such as NASH or NAFLD. The invention provides a therapeutic or prophylactic agent for fatty liver diseases that comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The invention also provides a therapeutic or prophylactic agent for adiposity that comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: August 6, 2018Date of Patent: July 27, 2021Assignees: Hiroshima University, Tokyo University of Pharmacy & Life Sciences, The University of TokyoInventors: Tomoichiro Asano, Yusuke Nakatsu, Hisanaka Ito, Takayoshi Okabe
-
Publication number: 20210115440Abstract: This is to provide a composition for delivering a nucleic acid and a nucleic acid-containing composition which ensure stability of a nucleic acid drug, have a high intracellular introduction rate, can efficiently express the function of a nucleic acid drug, and have low cytotoxicity. Disclosed is a composition for delivering a nucleic acid and a nucleic acid-containing composition each comprises a block copolymer in which a polyethylene glycol segment and a hydrophobic polyester segment are linked, and a peptide having 4 to 30 residues containing at least one selected from the group consisting of arginine and lysine.Type: ApplicationFiled: July 11, 2018Publication date: April 22, 2021Applicant: TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCESInventors: Takanori KANAZAWA, Yuuki TAKASHIMA, Hisako IBARAKI, Shunsuke SHIRAISHI, Ei NAKATA, Yusuke IRIYAMA, Keiichiro OTSUKA
-
Publication number: 20200383967Abstract: The purpose of the invention is to develop, as drug-candidate compounds, a group of novel compounds having the activity of inhibiting functions of Pin1. The invention provides: a compound represented by formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic or prophylactic agent for inflammatory diseases, a therapeutic or prophylactic agent for cancer, and a therapeutic or prophylactic agent for adiposity that use said compound/salt.Type: ApplicationFiled: August 6, 2018Publication date: December 10, 2020Applicants: Hiroshima University, Tokyo University of Pharmacy & Life Sciences, The University of TokyoInventors: Tomoichiro Asano, Yusuke Nakatsu, Hisanaka Ito, Takayoshi Okabe
-
Publication number: 20200383989Abstract: The purpose of the invention is to develop a novel therapeutic agent for fatty liver diseases such as NASH or NAFLD. The invention provides a therapeutic or prophylactic agent for fatty liver diseases that comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The invention also provides a therapeutic or prophylactic agent for adiposity that comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: August 6, 2018Publication date: December 10, 2020Applicants: Hiroshima University, Tokyo University of Pharmacy & Life Sciences, The University of TokyoInventors: Tomoichiro Asano, Yusuke Nakatsu, Hisanaka Ito, Takayoshi Okabe
-
Publication number: 20200383987Abstract: The purpose of the invention is to develop, as drug-candidate compounds, a group of novel compounds having the activity of inhibiting functions of Pin1. The invention provides: a compound represented by formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic or prophylactic agent for inflammatory diseases, a therapeutic or prophylactic agent for cancer, and a therapeutic or prophylactic agent for adiposity that use said compound/salt.Type: ApplicationFiled: August 6, 2018Publication date: December 10, 2020Applicants: Hiroshima University, Tokyo University of Pharmacy & Life Sciences, The University of TokyoInventors: Tomoichiro Asano, Yusuke Nakatsu, Hisanaka Ito, Takayoshi Okabe
-
Patent number: 10829512Abstract: The present invention provides a means capable of selectively introducing a disulfide bond with respect to two free thiol groups located in a molecule of an organic compound such as a peptide, or the like, in a short time by a simple treatment and also by a chemically stable method. A nitrogen-containing compound represented by Chemical Formula 1 below or a salt thereof: The symbols shown in Chemical Formula 1 are the same as defined in the specification.Type: GrantFiled: May 22, 2017Date of Patent: November 10, 2020Assignees: Tokyo University of Pharmacy & Life Sciences, Kokusan Chemical Co., Ltd.Inventors: Yoshio Hayashi, Akihiro Taguchi, Kentaro Fukumoto
-
Patent number: 10550153Abstract: To provide a peptide that selectively activates type 2 neuromedin U receptor and is chemically stable under physiological conditions. A peptide represented by Formula (1) described in the specification.Type: GrantFiled: January 19, 2018Date of Patent: February 4, 2020Assignees: TOKYO UNIVERSITY OF PHARMACY & LIFE SCIENCES, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, KYOTO PHARMACEUTICAL UNIVERSITYInventors: Yoshio Hayashi, Kentaro Takayama, Mikiya Miyazato, Kenji Kangawa, Kenji Mori, Akira Yamamoto, Toshiyasu Sakane
-
Publication number: 20190382330Abstract: An object of the present invention is to develop a therapeutic agent for an inflammatory disease such as an inflammatory bowel disease or NASH, which therapeutic agent shows less side effects and high effectiveness. The present invention provides a compound represented by Formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic agent or a prophylactic agent for an inflammatory disease, and a therapeutic agent or a prophylactic agent for colon cancer, containing the compound.Type: ApplicationFiled: November 29, 2017Publication date: December 19, 2019Applicants: Hiroshima University, Tokyo University of Pharmacy & Life Sciences, The University of TokyoInventors: Tomoichiro Asano, Yusuke Nakatsu, Hisanaka Ito, Takayoshi Okabe